Patent settlement curbs could reduce incentives to bring generics to market; report
A new white paper released this week, titled The Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment, by Jonathan Orszag and Bret Dickey of Compass Lexecon, shows that when companies consider bringing new generic medicines to market, the ability to settle patent litigation – also described as pay-for-delay deals - significantly influences their decision.
These findings are particularly timely as the US Senate Judiciary Committee’s Subcommittee on Antitrust, Competition Policy and Consumer Rights holds a hearing on limiting settlement options for generic pharmaceutical companies that pursue patent challenges. Report author Jonathan Orszag will be among those testifying.
Generics already make up 84% of prescriptions dispensed in USA, notes GPhA
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze